Combo PPI/NSAID Products May Escape Outcomes Studies Despite Split FDA Panel Vote
This article was originally published in The Pink Sheet Daily
Gastrointestinal Drugs Advisory Committee says endoscopically diagnosed ulcers are an appropriate surrogate endpoint for assessing the ability of gastroprotective agents to reduce NSAID-related GI toxicity but not for evaluating the comparative GI safety of NSAIDS.
You may also be interested in...
FDA’s bid to harmonize two review divisions’ regulatory approaches to assessing and preventing gastrointestinal toxicity caused by non-steroidal anti-inflammatory drugs has been thrown a curve by the agency’s outside experts.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.